Kimby Eva, Sverrisdottir Asgerdur, Elinder Göran
Department of Medicine, Division of Hematology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden.
Eur J Haematol. 2004 Apr;72(4):292-5. doi: 10.1111/j.1600-0609.2004.00214.x.
The optimal treatment of non-Hodgkin's lymphoma (NHL) during pregnancy is currently undefined. The potential teratogenic effects of conventional chemotherapy preclude its use during the first trimester of pregnancy. We report the case of a pregnant woman with relapsed indolent follicular NHL who was treated with rituximab (unintentionally) during the first trimester. The treatment stabilised the disease. Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab. Data of using rituximab during pregnancy are scarce, but the present case shows that rituximab may be one option for treatment of NHL in early pregnancy.
目前，孕期非霍奇金淋巴瘤（NHL）的最佳治疗方法尚不明确。传统化疗潜在的致畸作用使其无法在妊娠头三个月使用。我们报告了一例复发性惰性滤泡性NHL孕妇的病例，该孕妇在妊娠头三个月意外接受了利妥昔单抗治疗。治疗使病情稳定。经过顺利的孕期，足月产下一名健康婴儿，仔细的血液学和免疫学监测显示，接触利妥昔单抗未产生不良影响。孕期使用利妥昔单抗的数据很少，但本病例表明，利妥昔单抗可能是孕早期NHL治疗的一种选择。
